Pharmaron Forecasts Strong 2025 Revenue and Core Profit Growth Despite Drop in Headline Net Profit

Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) just unveiled an announcement.

Pharmaron Beijing Co., Ltd. has issued an estimate for its 2025 annual results, projecting revenue between RMB 13.87 billion and RMB 14.24 billion, representing a year-on-year increase of 13% to 16%. Despite this top-line growth and an expected 36% to 41% rise in net profit attributable to owners of the parent excluding non-recurring items, as well as a 10% to 15% increase in non-IFRS adjusted net profit, the company anticipates a 6% to 10% decline in reported net profit attributable to owners of the parent due to non-recurring gains or losses and other adjustments. The guidance highlights solid underlying operational momentum and improved core profitability, while signaling that headline net profit will be pressured by non-recurring factors, a distinction that is likely to be closely watched by investors assessing the company’s earnings quality and growth trajectory in the competitive pharmaceutical services sector.

The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.

More about Pharmaron Beijing Co., Ltd. Class H

Pharmaron Beijing Co., Ltd. is a China-based pharmaceutical research and development services provider, operating through a group structure to offer integrated R&D and related services to global drug developers. The company focuses on contract research, development and manufacturing solutions across the pharmaceutical value chain, targeting both domestic and international biopharma clients.

Average Trading Volume: 5,070,883

Technical Sentiment Signal: Buy

Current Market Cap: HK$58.34B

Learn more about 3759 stock on TipRanks’ Stock Analysis page.